Pfizer Faces Italian Antitrust Probe Over Xalatan Patent

Law360, New York (October 27, 2010, 10:58 AM ET) -- Italy's antitrust watchdog has opened an investigation into whether a Pfizer Inc. unit has improperly extended patent protection for Xalatan to shield the glaucoma treatment from generic competition.

L’Autorita Garante della Concorrenza e del Mercato revealed the probe Tuesday with surprise inspections at the headquarters of Pfizer's Italian unit following a complaint from Ratiopharm, a major European generic-drug maker.

According to the complaint, Pfizer Italia SRL took a number of steps to keep generic versions of Xalatan off the Italian market, including fraudulently seeking an extension...
To view the full article, register now.